LONDON—International investment
group Abingworth recently announced its seeding of GammaDelta Therapeutics Ltd, a new
immunotherapy company. Cancer Research Technology, King's College London and the Francis Crick Institute have also supported the new company. GammaDelta
was founded on research from Prof. Adrian Hayday and Dr. Oliver Nussbaumer at King’s College London and the Francis Crick Institute, funded in part by
Cancer Research UK. The research focuses on gamma delta cells, a unique, conserved population of lymphocytes that play a role in many immune responses and
immunopathologies. GammaDelta will leverage this research to develop improved immunotherapies for cancer and possibly other diseases as well.

Raj Mehta, founder and interim CEO of GammaDelta, said: “We are delighted to have attracted the support of Abingworth
to the founding and development of GammaDelta Therapeutics and will use the proceeds to help us advance our innovative programs into the
clinic.”